Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents

Cindy L. Grines, Robert O. Bonow, Donald E. Casey, Timothy J. Gardner, Peter B. Lockhart*, David J. Moliterno, Patrick O'Gara, Patrick Whitlow

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

71 Scopus citations

Abstract

Background and Overview. Dual antiplatelet therapy with aspirin and a thienopyridine has been shown to reduce cardiac events after coronary stenting. However, many patients and health care providers prematurely discontinue dual antiplatelet therapy, which greatly increases the risk of stent thrombosis, myocardial infarction and death. Conclusions and Clinical Implications. This advisory stresses the importance of 12 months of dual antiplatelet therapy after placement of a drug-eluting stent and educating patients and health care providers about hazards of premature discontinuation. It also recommends post-poning elective surgery for one year, and if surgery cannot be deferred, considering the continuation of aspirin during the perioperative period in high-risk patients with drug-eluting stents.

Original languageEnglish (US)
Pages (from-to)652-655
Number of pages4
JournalJournal of the American Dental Association
Volume138
Issue number5
DOIs
StatePublished - May 2007

Keywords

  • American Heart Association scientific statements
  • Anticoagulation therapy
  • Dental care
  • Myocardial infarction
  • Myocardial stunning
  • Stents
  • Thrombosis

ASJC Scopus subject areas

  • Dentistry(all)

Fingerprint

Dive into the research topics of 'Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents'. Together they form a unique fingerprint.

Cite this